Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Catalent stock
Learn how to easily invest in Catalent stock.
Catalent Inc is a drug manufacturers-specialty & generic business based in the US. Catalent shares (CTLT) are listed on the NYSE and all prices are listed in US Dollars. Catalent employs 19,000 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Catalent
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – CTLT – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Catalent stock price (NYSE: CTLT)Use our graph to track the performance of CTLT stocks over time.
Catalent shares at a glance
|Latest market close||$107.29|
|52-week range||$86.34 - $142.64|
|50-day moving average||$100.02|
|200-day moving average||$113.87|
|Wall St. target price||$138.15|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$2.77|
Buy Catalent shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Catalent stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Catalent price performance over time
|1 week (2022-06-24)||-2.12%|
|1 month (2022-05-28)||N/A|
|3 months (2022-03-30)||-3.19%|
|6 months (2021-12-31)||-16.20%|
|1 year (2021-07-01)||-3.21%|
|2 years (2020-07-01)||46.23%|
|3 years (2019-07-01)||96.11%|
|5 years (2017-06-30)||205.67%|
Is Catalent stock undervalued or overvalued?
Valuing Catalent stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Catalent's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Catalent's P/E ratio
Catalent's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 40x. In other words, Catalent shares trade at around 40x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Catalent's PEG ratio
Catalent's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.2685. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Catalent's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Catalent's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.1 billion.
The EBITDA is a measure of a Catalent's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$4.7 billion|
|Operating margin TTM||16.93%|
|Gross profit TTM||$1.4 billion|
|Return on assets TTM||5.21%|
|Return on equity TTM||11.79%|
|Market capitalisation||$19.6 billion|
TTM: trailing 12 months
Catalent share dividends
We're not expecting Catalent to pay a dividend over the next 12 months.
Catalent share price volatility
Over the last 12 months, Catalent's shares have ranged in value from as little as $86.34 up to $142.64. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Catalent's is 1.426. This would suggest that Catalent's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Catalent, Inc. , together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services.
Catalent in the news
Catalent (CTLT) Expands Packaging Capabilities at Japan Facility
3 Reasons to Retain Catalent (CTLT) Stock in Your Portfolio
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Frequently asked questionsWhat percentage of Catalent is owned by insiders or institutions?
Currently 0.25% of Catalent shares are held by insiders and 108.226% by institutions. How many people work for Catalent?
Latest data suggests 19,000 work at Catalent. When does the fiscal year end for Catalent?
Catalent's fiscal year ends in June. Where is Catalent based?
Catalent's address is: 14 Schoolhouse Road, Somerset, NJ, United States, 08873 What is Catalent's ISIN number?
Catalent's international securities identification number is: US1488061029 What is Catalent's CUSIP number?
Catalent's Committee on Uniform Securities Identification Procedures number is: 148806102
More guides on Finder
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
How to buy Warrantee (WRNT) stock when it goes public
Everything we know about the Warrantee IPO, plus information on how to buy in.
How to buy Treasure Global (TGL) stock when it goes public
Everything we know about the Treasure Global IPO, plus information on how to buy in.
How to buy BIOLIFE4D (SAVU) stock when it goes public
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
Ask an Expert